Alkem Labs Q3 FY26 Earnings Call Transcript Released; Enters MedTech with Occlutech Acquisition
Alkem Laboratories reported Q3 FY26 revenue of ₹3,736.8 crore, up 10.7% YoY. The company announced its entry into the medical devices sector by acquiring a 55% stake in Occlutech for an investment of ₹200-300 crore over 3-4 years. Occlutech is expected to achieve 20-25% EBITDA margins within 3-5 years. Domestic sales grew 5.5% to ₹2,495.9 crore.
The acquisition of Occlutech marks a significant strategic diversification into the medical devices market, which is a new and potentially high-growth area for Alkem Laboratories, impacting its future business profile and revenue streams.
The company reported positive revenue growth and announced a strategic acquisition into the growing MedTech sector, indicating a positive outlook and expansion.
Alkem Laboratories Limited has released the transcript for its Q3 FY26 Earnings Conference Call, which was held on February 13, 2026. The call detailed the company's financial performance and strategic initiatives, including a significant entry into the medical devices sector through the acquisition of Occlutech.
During the call, the management highlighted a stable performance in Q3 FY26, with total revenue reaching ₹3,736.8 crore, marking a year-on-year growth of 10.7%. International sales grew by 26.6% to ₹1,215.7 crore, while India sales stood at ₹2,495.9 crore, a 5.5% year-on-year increase. EBITDA was reported at ₹828 crore, with a margin of 22.2%. Net profit stood at ₹636 crore, a 1.6% year-on-year growth. An exceptional item of ₹52.8 crore was noted due to the Government of India's Labour Codes notification.
The company announced its foray into the medical devices market with the acquisition of Occlutech, a move described as a strategic expansion into a $10 billion Indian market with significant growth potential. Alkem aims to leverage Occlutech's expertise in interventional cardiology, particularly in treating septal defects, heart failure, and stroke prevention. The company plans to invest an additional ₹200-300 crore in Alkem MedTech over the next 3-4 years, with a significant portion of the investment already made. Occlutech is projected to achieve an EBITDA margin of 20-25% within 3-5 years and is expected to be EBITDA positive in the calendar year 2026. Alkem acquired a 55% stake in Occlutech, with plans to potentially increase its stake in the future. The company also anticipates launching new products, including a Left Atrial Appendage occluder, with a projected market size of $1.4 billion.
Alkem Laboratories Limited also provided insights into its domestic business, noting a YTD growth of approximately 10%. The chronic business continues to show strong growth, and the prescription business is performing well, gaining market share across specialties. The company is also preparing for the launch of semaglutide.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.